Expert Review of Neurotherapeutics

The case for realistic modeling in understanding seizures
pp. 1771-1773(3)
Authors: Thomas, Evan Alexander; Petrou, Steven

RNA analysis in neuronal dendrites: insights into Parkinson's disease
pp. 1775-1777(3)
Authors: Sharma, Anup; Eberwine, James

Immune markers for Huntington's disease?
pp. 1779-1781(3)
Authors: Wild, Edward; Björkqvist, Maria; Tabrizi, Sarah J

News in brief
pp. 1783-1785(3)

Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence
pp. 1787-1797(11)
Authors: Kamath, Jayesh; Handratta, Venkatesh

Pregnancy in Parkinson's disease: case report and discussion
pp. 1799-1805(7)
Authors: Robottom, Bradley J; Mullins, Roger J; Shulman, Lisa M

Noninvasive and minimally invasive detection and monitoring of peripheral neuropathies
pp. 1807-1816(10)
Author: Herrmann, David N

Treatment of status epilepticus
pp. 1817-1827(11)
Authors: Miller, Laura C; Drislane, Frank W

What's in the pipeline for the treatment of Parkinson's disease?
pp. 1829-1839(11)
Authors: Sommer, David B; Stacy, Mark A

The search for biomarkers in Parkinson's disease: a critical review
pp. 1841-1852(12)
Authors: Antoniades, Chrystalina A; Barker, Roger A

Single photon-emission computed tomography imaging in early Parkinson's disease
pp. 1853-1864(12)
Authors: Antonini, Angelo; Isaias, Ioannis U

Commonalities in the genetics of Alzheimer's disease and Parkinson's disease
pp. 1865-1877(13)
Authors: Grünblatt, Edna

Memory loss in Alzheimer's disease: implications for development of therapeutics
pp. 1879-1891(13)
Authors: Gold, Carl A; Budson, Andrew E

Acknowledgements
pp. 1905-1905(1)